NEW YORK, July 26, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been
filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to
request that the court appoint you as lead plaintiff.
PolarityTE, Inc. (NASDAQ:COOL)
Class Period: March 31, 2017 to June 22, 2018
Lead Plaintiff Deadline: August 27, 2018
The lawsuit alleges that PolarityTE, Inc. made materially false and/or misleading statements and/or failed to
disclose that: (i) the status of Patent #14/954,335 at the time it was acquired by the Company on April 7, 2017 and the months
following; (ii) the updated status of Patent #14/954,335 after its June 4, 2018 final rejection by the United States Patent Office;
and (iii) that as a result of the foregoing, PolarityTE's publicly disseminated financial statements were materially false and
misleading.
Get additional information about the COOL lawsuit: http://www.kleinstocklaw.com/pslra-c/polarityte-inc?wire=3
Restoration Robotics, Inc. (NASDAQ:HAIR)
Class Period: Pursuant to the IPO between October 12, 2017 and October 16, 2017
Lead Plaintiff Deadline: August 21, 2018
The complaint alleges that Restoration Robotics negligently issued untrue statements of material facts in, and
omitted to state material facts required to be stated from, the Offering Materials issued in connection with the Initial Public
Offering. The complaint further alleges that as a result of the materially misleading Offering Materials, the Company’s stock price
was artificially inflated at the time of the IPO.
Get additional information about the HAIR lawsuit: http://www.kleinstocklaw.com/pslra-c/restoration-robotics-inc-hair?wire=3
Sibanye Gold Limited (NYSE:SBGL)
Class Period: April 7, 2017 to June 26, 2018
Lead Plaintiff Deadline: August 27, 2018
The complaint alleges that throughout the class period Sibanye Gold Limited made materially false and/or
misleading statements and/or failed to disclose that: (1) Sibanye’s safety protocols were inadequate to prevent a high rate of
worker death; (2) Sibanye’s mining supervisors routinely forced Company employees to work in unsafe and unlawful conditions; the
foregoing issues would foreseeably subject Sibanye to heightened regulatory oversight; and (3) as a result, Sibanye’s public
statements were materially false and misleading at all relevant times.
Get additional information about the SBGL lawsuit: http://www.kleinstocklaw.com/pslra-c/sibanye-gold-limited?wire=3
Gogo Inc. (NASDAQ:GOGO)
Class Period: February 27, 2017 to May 7, 2018
Lead Plaintiff Deadline: August 27, 2018
During the class period, Gogo Inc. allegedly made materially false and/or misleading statements and/or failed to
disclose that: (1) Gogo’s 2Ku antenna had more reliability issues than the public was led to believe; (2) Gogo’s 2Ku antennas
required costly installation and faced costly remediation challenges or required replacement due to deicing fluids from planes
infiltrating the 2Ku system, as well as manufacturing and software issues; (3) consequently, Gogo would not be able to meet its
previously issued 2018 guidance; and (4) as a result, the company’s financial statements were materially false and misleading at
all relevant times.
Get additional information about the GOGO lawsuit: http://www.kleinstocklaw.com/pslra-c/gogo-inc?wire=3
Flex Pharma, Inc. (NASDAQ:FLKS)
Class Period: November 6, 2017 to June 12, 2018
Lead Plaintiff Deadline: August 20, 2018
The complaint alleges Flex Pharma, Inc. made materially false and/or misleading statements and/or failed to
disclose that: (i) the Company overstated the viability and approval prospects for its product candidate FLX-787 for the treatment
of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease; and (ii) as a result, Flex's public statements were materially
false and misleading at all relevant times.
On June 13, 2018, Flex announced that it planned to halt its FLX-787 trials, citing oral tolerability concerns
observed in both studies. Flex also said that it will restructure its organization to reduce costs, including reducing its
workforce by approximately 60%, and that Flex's Board is exploring "strategic alternatives, including the potential sale or merger
of the company." Following this news, Flex stock dropped $3.14 per share, or 75.12%, to close at $1.04 on June 13, 2018.
Get additional information about the FLKS lawsuit: http://www.kleinstocklaw.com/pslra-c/flex-pharma-inc?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or
obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph
Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud
throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
